CFO Daniella Beckman exit terms at Tango Therapeutics (NASDAQ: TNGX)

Rhea-AI Filing Summary

FAQ

Filing Exhibits & Attachments

8-K Event Classification

Key Figures

Key Terms

What did Tango Therapeutics (TNGX) disclose about its CFO change?

What severance will former CFO Daniella Beckman receive from Tango Therapeutics (TNGX)?

How does Tango Therapeutics (TNGX) handle COBRA benefits in the CFO separation?

What happens to Daniella Beckman’s equity awards after leaving Tango Therapeutics (TNGX)?

How long can the former CFO exercise her Tango Therapeutics (TNGX) stock options?

Is there a release requirement in the Tango Therapeutics (TNGX) CFO separation agreement?

Agreements & Contracts

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Tango Therapeutics, Inc. entered into a Separation Agreement and Release with former Chief Financial Officer Daniella Beckman on May 7, 2026, following the Board’s earlier decision that she would cease serving as CFO, principal accounting officer and principal financial officer effective April 15, 2026.

Under the agreement and her employment contract, Ms. Beckman will receive 12 months of severance pay at her current base salary, paid in installments, plus reimbursement of monthly COBRA premiums for up to 12 months. The company will also accelerate the vesting of her outstanding stock options and restricted stock units to reflect an additional 24 months of continued service from her May 1, 2026 employment end date and extend the post-termination stock option exercise period through August 31, 2026, in exchange for her signing a general release in favor of the company.

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Severance duration: 12 months COBRA reimbursement period: 12 months Additional vesting service credit: 24 months +4 more

7 metrics

Severance duration 12 months Severance pay at current base salary

COBRA reimbursement period 12 months Reimbursement of monthly COBRA premiums

Additional vesting service credit 24 months Equity vesting as if 24 more months of service

Last day of employment May 1, 2026 Ms. Beckman’s employment end date

CFO role end date April 15, 2026 Effective date she ceased serving as CFO

Separation Agreement date May 7, 2026 Date Separation Agreement and Release was executed

Option exercise deadline August 31, 2026 End of extended post‑termination exercise period

Separation Agreement and Release, COBRA, restricted stock unit, post-termination exercise period, +1 more

5 terms

Separation Agreement and Release financial

"the Company and Ms. Beckman entered into a Separation Agreement and Release"

COBRA financial

"reimbursement for any monthly COBRA premium payments for up to 12 months"

COBRA is a U.S. federal law that lets employees and their dependents temporarily keep employer-sponsored health insurance after job loss, reduction in hours, or other qualifying events by paying the premiums themselves. Investors should care because offering COBRA can affect a company’s cash flow, administrative costs and legal disclosures when workforce changes occur—similar to a former club member paying to keep their membership active after leaving the club.

restricted stock unit financial

"outstanding option and restricted stock unit awards that would have otherwise vested"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

post-termination exercise period financial

"extend the post-termination exercise period for any of Ms. Beckman’s vested stock options"

general release financial

"In order to receive the foregoing benefits, Ms. Beckman executed a general release"

Understanding 8-K Material Events →

05/08/2026 - 09:22 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 7, 2026

TANGO THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-39485

85-1195036

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

201 Brookline Ave., Suite 901

Boston, MA

02215

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: 857-320-4900

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.001 par value

TNGX

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Separation Agreement

As previously announced, on April 10, 2026, the board of directors (the “Board”) of Tango Therapeutics, Inc. (the “Company”) determined that Daniella Beckman will no longer serve as the Company’s Chief Financial Officer, principal accounting officer and principal financial officer, effective as of April 15, 2026.

In connection with Ms. Beckman’s separation, on May 7, 2026, the Company and Ms. Beckman entered into a Separation Agreement and Release (the “Separation Agreement”). Pursuant to the terms of the Separation Agreement and to the terms of that certain Employment Agreement by and between the Company and Ms. Beckman, the Company has agreed to provide certain benefits to Ms. Beckman, including the following: (i) twelve months of severance pay at Ms. Beckman’s current base salary, paid out in substantially equal installments over 12 months and (ii) reimbursement for any monthly COBRA premium payments for up to 12 months. The Company also agreed to accelerate the vesting of such number of Ms. Beckman’s outstanding option and restricted stock unit awards that would have otherwise vested had Ms. Beckman remained in continuation of her service with the Company for an additional twenty-four months following May 1, 2026, Ms. Beckman’s last day of employment with the Company. In addition, the Company agreed to extend the post-termination exercise period for any of Ms. Beckman’s vested stock options as of the date of the Separation Agreement through August 31, 2026.

In order to receive the foregoing benefits, Ms. Beckman executed a general release in favor of the Company.

The foregoing description of the terms and conditions of the Separation Agreement does not purport to be complete and is qualified in its entirety by the Separation Agreement, which is attached hereto as Exhibit 10.1 and incorporated by reference herein.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.


Exhibit Number		Description of Exhibit

10.1		Separation Agreement, dated as of May 7, 2026 by and between the Company and Daniella Beckman.

104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Source: View Original Filing on SEC EDGAR

Tango Therapeutics disclosed that its Board previously decided Daniella Beckman would stop serving as Chief Financial Officer on April 15, 2026. The company then signed a Separation Agreement on May 7, 2026, outlining her severance, benefits, and equity treatment.

Under the Separation Agreement, Daniella Beckman will receive 12 months of severance pay at her current base salary. The payments will be made in substantially equal installments over a 12‑month period, consistent with the terms of her employment agreement.

Tango Therapeutics agreed to reimburse Daniella Beckman for any monthly COBRA premium payments for up to 12 months. This reimbursement supports continued health coverage for a defined period following her May 1, 2026 employment end date.

The company will accelerate vesting of Ms. Beckman’s outstanding stock options and restricted stock units as if she had continued service for an additional 24 months after May 1, 2026. This increases the portion of her existing equity awards that become fully vested.

Tango Therapeutics extended the post‑termination exercise period for Daniella Beckman’s vested stock options through August 31, 2026. This gives her additional time beyond her departure date to decide whether to exercise previously vested options.

Yes. To receive severance, COBRA reimbursement, accelerated vesting, and the extended option exercise period, Daniella Beckman executed a general release in favor of Tango Therapeutics. This release is a standard condition in many executive separation arrangements.

4 documents

Tango Therapeutics, Inc.

Date: May 8, 2026

/s/ Malte Peters

Malte Peters, M.D.

President and Chief Executive Officer

EX-10.1 EX-10.1 48.9 KB